Skip to content

Adaptin Bio, Inc.: 10-Q filed 2025-11-14

What Adaptin Bio, Inc. reported in its quarterly report filed 2025-11-14 (fiscal Q3 2025): 29 published measures, 90 facts as tagged in accession 0001213900-25-110559.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-14
Fiscal period
fiscal Q3 2025
Accession
0001213900-25-110559 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Adaptin Bio, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-30979,474USD
At 2024-12-31239,415USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-301,860,552USD
At 2024-12-314,339,531USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-30-881,078USD
At 2025-06-30474,409USD
At 2025-03-311,745,264USD
At 2024-12-31-4,100,116USD
At 2024-09-30-3,243,280USD
At 2024-06-30-2,135,729USD
At 2024-03-31-1,316,991USD
At 2023-12-31-977,559USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-30579,089USD
At 2024-12-3134,085USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,675,612USD92
2025-01-01 to 2025-09-30-3,799,551USD273
2025-04-01 to 2025-06-30-1,520,855USD91
2025-01-01 to 2025-03-31-603,084USD90
2024-07-01 to 2024-09-30-1,107,551USD92
2024-01-01 to 2024-09-30-2,265,721USD274
2024-04-01 to 2024-06-30-818,738USD91
2024-01-01 to 2024-03-31-339,432USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-4,075,016USD273
2024-01-01 to 2024-09-30-761,936USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-304,620,020USD273
2024-01-01 to 2024-09-30872,490USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-7,923,783USD
At 2024-12-31-4,124,232USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-308,455,829shares92
2025-01-01 to 2025-09-307,588,793shares273
2024-07-01 to 2024-09-303,249,999shares92
2024-01-01 to 2024-09-303,249,999shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-308,455,829shares92
2025-01-01 to 2025-09-307,588,793shares273
2024-07-01 to 2024-09-303,249,999shares92
2024-01-01 to 2024-09-303,249,999shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.2USD/shares92
2025-01-01 to 2025-09-30-0.5USD/shares273
2024-07-01 to 2024-09-30-0.34USD/shares92
2024-01-01 to 2024-09-30-0.7USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.2USD/shares92
2025-01-01 to 2025-09-30-0.5USD/shares273
2024-07-01 to 2024-09-30-0.34USD/shares92
2024-01-01 to 2024-09-30-0.7USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-30320,125USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,675,612USD92
2025-01-01 to 2025-09-30-4,046,925USD273
2024-07-01 to 2024-09-30-994,749USD92
2024-01-01 to 2024-09-30-2,061,805USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-30979,474USD
At 2024-12-3145,539USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-301,860,552USD
At 2024-12-314,339,531USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-301,338,076USD
At 2024-12-311,361,081USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,675,612USD92
2025-01-01 to 2025-09-304,046,925USD273
2024-07-01 to 2024-09-30994,749USD92
2024-01-01 to 2024-09-302,061,805USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-30778,664USD92
2025-01-01 to 2025-09-301,181,131USD273
2024-07-01 to 2024-09-30682,546USD92
2024-01-01 to 2024-09-301,566,533USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-308,455,829shares
At 2024-12-313,249,999shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-30579,089USD
At 2024-12-3134,085USD
At 2024-09-30115,308USD
At 2023-12-314,754USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-307,041,859USD
At 2024-12-3123,791USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-30522,476USD
At 2024-12-311,049,910USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-30400,385USD
At 2024-12-3111,454USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,675,612USD92
2025-01-01 to 2025-09-30-3,799,551USD273
2024-07-01 to 2024-09-30-1,107,551USD92
2024-01-01 to 2024-09-30-2,265,721USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30896,948USD92
2025-01-01 to 2025-09-302,865,794USD273
2024-07-01 to 2024-09-30312,203USD92
2024-01-01 to 2024-09-30495,272USD274

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-01-01 to 2025-09-3072,659USD273
2024-07-01 to 2024-09-30106,553USD92
2024-01-01 to 2024-09-30195,161USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-01-01 to 2025-09-30247,374USD273
2024-07-01 to 2024-09-30-112,802USD92
2024-01-01 to 2024-09-30-203,916USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-309,584USD273

Inspect the source

Entity
Adaptin Bio, Inc. / CIK 0001938571
Captured
2026-09-21T17:35:35.805Z
SEC response SHA-256
0eb03b88a99a94afd0b295104043bff1b217616b21ccffd97a8a687df1275f81

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001938571.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))